Stabilization of vasoactive intestinal peptide by lipids

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 2, 1998, Pages 753-758

  Gololobov, Gennady ^a   Noda, Yasuko ^a   Sherman, Simon ^a   Rubinstein, Israel ^c   Baranowska Kortylewicz, Janina ^b   Paul, Sudhir ^a,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPID; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BINDING AFFINITY; CHEMICAL REACTION KINETICS; CIRCULAR DICHROISM; DRUG CONFORMATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOMETRY;

AMINO ACID SEQUENCE; DRUG STABILITY; LIPOSOMES; MOLECULAR SEQUENCE DATA; PHOSPHATIDYLGLYCEROLS; PROTEIN CONFORMATION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031809309     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Barnes PJ and Dixon CMS (1984) The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis 130:162-166.
2. Bolin DR, Michalewsky J, Wasserman MA and O'Donnell M (1995) Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37:57-66.
3. Brenneman DE, Nicol T, Warren D and Bowers LM (1990) Vasoactive intestinal peptide: A neurotrophic releasing agent and an astroglial mitogen. J Neurosci Res 25:386-394.
4. Caughey GH, Leidig F, Viro NF and Nadel JA (1988) Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 244:133-137.
5. Crowe R, Lincoln J, Blacklay PF, Pryor JP, Lumley JSP and Burnstock G (1983) Vasoactive intestinal polypeptide-like immunoreactive nerves in diabetic penis. Diabetes 32:1075-1077.
6. Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell J, Lux G and Strunz U (1978) Vasoactive intestinal peptide in man: Pharmacokinetics, metabolic and circulatory effects. Gut 19:1049-1053.
7. Gao Q-S, Sun M, Tyutyulkova S, Webster D, Rees A, Tramontano A, Massey R and Paul S (1994) Molecular cloning of a proteolytic antibody light chain. J Biol Chem 269:32389-32393.
8. Gao X-P, Noda Y, Rubinstein I and Paul S (1994) Vasoactive intestinal peptide encapsulated in liposomes: Effects on systemic arterial blood pressure. Life Sci (Pharmacol Lett) 54:247-252.
9. Gerstenberg TC, Metz P, Ottesen B and Fahrenkrug J (1992) Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 147:1277-1279.
10. Hachisu M, Hiranuma T, Tani S and Iizuka T (1991) Enzymatic degradation of helodermin and vasoactive intestinal polypeptide. J Pharmacobio-Dyn 14:126-131.
11. 131I-VIP in the rat studied by gamma-camera. Nucl Med Biol 21:865-872.
12. Heinz EP, Dey RD, Flux M and Said SI (1985) Deficient vasoactive intestinal peptide innervation in the sweat glands of cystic fibrosis patients. Science (Wash DC) 229:1407-1408.
13. McMaster D, Suzuki Y, Rorstad O and Lederism K (1987) Iodinated derivatives of vasoactive intestinal peptide (VIP), PHI and PHM: Purification, chemical characterization and biological activity. Peptides 8:663-676.
14. Miguel A, Lopez-Gonzalez JR, Calvo CO, Amalia R and Guerrero JM (1992) Melatonin potentiates cyclic AMP production stimulated by vasoactive intestinal peptide in human lymphocytes. Neuroscience Lett 136:150-152.
15. Mitchell SJ, Modlin IM, D'Sa Barros AAJ and Bloom SR (1982) The pharmacokinetics of VIP in dog and pig. Experientia 38:1091-1093.
16. Mody RK, Tramontano A and Paul S (1994) Spontaneous hydrolysis of vasoactive intestinal peptide in neutral aqueous solution. Int J Pept Protein Res 44:441-447.
17. Morice A, Unwin J and Sever PS (1983) Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2:1225-1227.
18. Musso GF, Patthi S, Ryskamp TC, Provow S, Kaiser ET and Velicelebi G (1988) Development of helix-based vasoactive intestinal peptide analogues: Identification of residues required for receptor interaction. Biochemistry 27:8174-8181.
19. Nishi N, Tsutsumi A, Morishige M, Kiyama S, Fujii N, Takeyama M and Yajima H (1983) Apparent autolysis of the N-terminal tetrapeptide of vasoactive intestinal polypeptide (VIP). Chem Pharm Bull 31:1067-1072.
20. Noda Y, Rodriguez-Sierra J, Liu J, Landers D, Mori A and Paul S (1994) Partitioning of vasoactive intestinal polypeptide into lipid bilayers. Biochim Biophys Acta 1191:324-330.
21. Ollerenshaw S, Jarvis D, Woolcock A, Sullivan C and Scheibner T (1989) Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med 320:1244-1248.
22. Paul S and Ebadi M (1993) Vasoactive intestinal peptide: Its interactions with calmodulin and catalytic antibodies. Neurochem Int 23:197-214.
23. Paul S, Sun M, Mody R, Eklund SH, Beach CM, Massey RJ and Hamel F (1991) Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies. J Biol Chem 266:16128-16134.
24. Reubi JC (1995) In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J Nucl Med 36:1846-1853.
25. Robinson RM, Blakeney EW Jr and Mattice WL (1982) Lipid-induced conformational changes in glucagon, secretin and vasoactive intestinal peptide. Biopolymers 21: 1217-1228.
26. Sansom MS (1991) The biophysics of peptide models of ion channels. Prog Biophys Mol Biol 55:139-235.
27. Sejourne F, Rubinstein I, Suzuki H and Alkan-Onyuksel H (1997) Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm Res 14:362-365.
28. Sreerama N and Woody RW (1993) A self consistent method for the analysis of protein secondary structure from circular dichroism. Anal Biochem 209:32-44.
29. Surrenti C, Renzi D, Garcea MR, Surrenti E and Salvadori G (1993) Colonic vasoactive intestinal polypeptide in ulcerative colitis. J Physiology 87:307-311.
30. Suzuki H, Noda Y, Gao X-P, Sejourne F, Alkan-Onyuksel H, Paul S and Rubinstein I (1996) Encapsulation of VIP into liposomes restores vasorelaxant in hypertension in situ. Am J Physiol (Heart Circ. Physiol. 40) 271:H282-H287.
31. Tam EK, Franconi GM, Nadel JA and Caughey GH (1990) Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am J Respir Cell Mol Biol 2:449-452.
32. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W and Valent P (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331:1116-1121.
33. Yanaihara N ed. (1992) Vasoactive intestinal peptide and related peptides. Biomed Res 13:suppl 2.